Background & aims: Early recurrence of hepatocellular carcinoma (HCC) after curative resection is common. However, the association between genetic mechanisms and early HCC recurrence, especially in Chinese patients, remains largely unknown.
Methods: We performed whole-genome sequencing (49 cases), whole-exome sequencing (18 cases), and deep targeted sequencing (115 cases) on 182 primary HCC samples. Focusing on WNK2, we used Sanger sequencing and qPCR to evaluate all the coding exons and copy numbers of that gene in an additional 554 HCC samples. We also explored the functional effect and mechanism of WNK2 on tumor growth and metastasis.
Results: We identified 5 genes (WNK2, RUNX1T1, CTNNB1, TSC1, and TP53) harboring somatic mutations that correlated with early tumor recurrence after curative resection in 182 primary HCC samples. Focusing on WNK2, the overall somatic mutation and copy number loss occurred in 5.3% (39/736) and 27.2% (200/736), respectively, of the total 736 HCC samples. Both types of variation were associated with lower WNK2 protein levels, higher rates of early tumor recurrence, and shorter overall survival. Biofunctional investigations revealed a tumor-suppressor role of WNK2: its inactivation led to ERK1/2 signaling activation in HCC cells, tumor-associated macrophage infiltration, and tumor growth and metastasis.
Conclusions: Our results delineate genomic events that characterize Chinese HCCs and identify WNK2 as a driver of early HCC recurrence after curative resection.
Lay summary: We applied next-generation sequencing and conducted an in-depth genomic analysis of hepatocellular carcinomas from a Chinese patient cohort. The results delineate the genomic events that characterize hepatocellular carcinomas in Chinese patients and identify WNK2 as a driver associated with early tumor recurrence after curative resection.
Keywords: Early Recurrence; Hepatocellular Carcinoma; Sequencing; WNK2.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma.Hum Pathol. 2018 Nov;81:37-46. doi: 10.1016/j.humpath.2018.06.026. Epub 2018 Jun 24. Hum Pathol. 2018. PMID: 29949741
Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.Gastroenterology. 2019 Dec;157(6):1630-1645.e6. doi: 10.1053/j.gastro.2019.09.005. Epub 2019 Sep 24. Gastroenterology. 2019. PMID: 31560893
Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.Gastroenterology. 2017 Jul;153(1):249-262.e2. doi: 10.1053/j.gastro.2017.03.024. Epub 2017 Mar 29. Gastroenterology. 2017. PMID: 28363643
Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.World J Gastroenterol. 2013 Dec 21;19(47):8873-9. doi: 10.3748/wjg.v19.i47.8873. World J Gastroenterol. 2013. PMID: 24379610 Free PMC article. Review.
Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.Cancer Lett. 2013 Nov 1;340(2):247-53. doi: 10.1016/j.canlet.2012.09.027. Epub 2012 Oct 12. Cancer Lett. 2013. PMID: 23063663 Review.
Cited by 2 articles
SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.Theranostics. 2020 Mar 25;10(10):4627-4643. doi: 10.7150/thno.42869. eCollection 2020. Theranostics. 2020. PMID: 32292519 Free PMC article.
MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3β/β-catenin signaling.NPJ Genom Med. 2020 Apr 1;5:15. doi: 10.1038/s41525-020-0122-7. eCollection 2020. NPJ Genom Med. 2020. PMID: 32257385 Free PMC article.